The Burden of Chronic Kidney Disease on Developing Nations: A 21st Century Challenge in Global Health

Rachel A. Nugent a Sana F. Fathima c Andrea B. Feigl c Dorothy Chyung b

a Center for Global Development, Washington, D.C., and b Cornell Weill School of Medicine, New York, N.Y., USA; c University of Oxford, Oxford, UK

Introduction to Chronic Diseases

The pattern of disease burden in the 21st century has significantly shifted towards chronic diseases (CDs) 1 [1]. Population aging and lifestyle-modifiable risk factors, accompanied by a decline in early-life infectious diseases, have resulted in the emergence of CDs as a major global health threat [2]. Both morbidity and mortality of CDs are rising, escalated by the increasing prevalence of pandemic health problems such as diabetes mellitus (DM) and cardiovascular disease (CVD). The expected increase in the burden of CDs is likely to have profound socioeconomic and public health consequences, especially in developing countries [3].

CDs are often considered to be a health problem endemic to the developed world, but the etiological link between infectious diseases and CDs and the global rise of DM, CVD, and nondiabetic chronic renal diseases have made CDs a primary health burden in developing countries [4]. Advances in medical innovation, focus on nutri-

1 In this context, CDs are defined as noncommunicable diseases that persist for long durations of time, such as CKD and CVD. The WHO describes CDs as type 2 diseases.

2 Developing countries, also referred to as low- and middle-income countries, are defined by criteria established by the World Bank.
tional health, economic improvement, and urbanization have resulted in a major surge in life expectancy and improvement in quality of life. These advances are countered by increased exposure to risk factors associated with CDs, such as unhealthy diets and lack of physical activity [5].

Among CDs, chronic kidney disease (CKD) is of particular significance and contributes heavily to the global CVD and end-stage renal disease (ESRD) [6, 7]. CKD ultimately progresses to ESRD, the rate of which is dependent on coexisting pathologies and risk factors [6]. Jungers et al. [8] found that the incidence of de novo CVD events in a non–ESRD cohort of CKD patients was 41% in men and 19% in women over a 10-year span. As documented by Foley et al. [9], the prevalence of CVD in ESRD and end-stage CKD patients increases to 74%. CKD is a burden not just for renal replacement therapy (RRT) demands but also for overall population health. Currently, CKD is the 12th highest cause of death and 17th highest cause of disability worldwide [6]. However, the rapid surge in diabetes and hypertension (HT), both of which are predicted to drive epidemics in CKD and CVD, will dramatically escalate this burden. CKD is expected to be a profound 21st century medical challenge [10].

As the global health paradigm shifts towards CDs, the current development aid for health focus on infectious diseases [3] is no longer a sustainable approach in developing countries. The impact of CDs is overwhelming and there is a dire need for a greater alignment of funding with the burden of CDs. Coordinated and integrated action to target the growing prevalence of CDs will become essential in 21st century global public health policy.

### Chronic Kidney Disease

CKD [4] is a complex and progressive condition [11] that arises from both noncommunicable diseases [5] (fig. 1) and infectious diseases, such as malaria, schistosomiasis,
HIV, and hepatitis B [12, 13]. The use of herbal nephrotoxic medications, such as those containing aristolochic acid, also contributes to CKD (odds ratio = 2.19) [14]. Studies suggest that CKD may be a risk multiplier for infectious disease-associated mortality primarily in developing countries, which face comparatively higher infectious disease-associated mortality primarily in developing countries [7]. However, infectious sources of CKD are still less common than chronic sources of CKD, especially in developing nations, where the many significant risk factors associated with kidney disease, such as HT, DM, dyslipidemia, and obesity, are becoming increasingly prevalent. It is characterized by stages of irreversible and impaired renal function, with the progression of renal function deterioration leading to ESRD, which is life-threatening without proper RRT intervention [15]. Stages 1 and 2 of CKD (covert CKD), as defined by the level of kidney function, are often asymptomatic and diagnosed by the presence of micro- and macroalbuminuria, which are markers for diffuse vascular damage and microinflammation associated with cardiokidney damage [13]. Covert CKD diagnosis is often a result of routine screening practices and generally targeted at high-risk patients [16].

Patients suffering from reduced kidney function, most often as a result of DM or HT, represent a global population that is highly vulnerable to CKD and ESRD and at great risk for many other CDs such as CVD [6, 17]. The AusDiab study [18] showed that the prevalence of CKD markers in the Australian population was 12.1% – a result similar to that of the NHANES III study findings of 11% in the United States [10]. Studies in China suggest that between 12.1 [19] and 13% [20] of the population have evidence of CKD and kidney damage markers. The profound impact of CKD on CDs and cardiovascular morbidity makes it especially important in the context of global disease, specifically in developing countries that have a mounting incidence of CKD-associated risk factors [21, 22].

### The Health Burden of CKD on Developing Countries

Generally, the disease pattern shifts from infectious to chronic conditions as a country becomes more ‘developed’ [23]. However, in many of the poorest nations, the epidemiological shift to CDs as the major cause of morbidity and mortality is increasingly evident in spite of low overall indicators of development. Sixty percent of the 58 million deaths in 2005 were attributed to CDs, with 4 out of 5 deaths globally occurring in low- and middle-income countries (LMICs) [24]. By 2030, it is expected that 3 out of 4 leading causes of death will be due to chronic conditions, indicating an alarming health burden [2]. Due to the escalating prevalence of CD risk factors, many developing countries now simultaneously bear the burden of both chronic and infectious diseases [25].

Currently, CVD and DM make up the largest contribution to the global CD burden. Developing countries such as India and China are major reservoirs for these CDs, with their incidence rising rapidly [26]. In China, between 1986 and 1999, age-specific death rates from circulatory diseases increased from 200 to 300% in those aged 35–44 years [27]. Ischemic heart disease and stroke mortality predictions between 1990 and 2020 include more than 100% increases in Latin America, the Middle East, and sub-Saharan Africa [28]. It is expected that the number of individuals with HT will increase from 972 million to 1.56 billion people by 2025. In 2000, the incidence of diabetes was estimated to be 171 million and WHO predictions expect this to increase to 366 million by 2030 [6]; 298 million of these individuals will be in developing countries [29].

Figure 2 offers a visual representation of the geographic burden of kidney disease in the world. Table 1 shows the population incidences of all stages of CKD in several developing countries. India, with the highest incidences of diabetes and HT in the world, is likely to face a catastrophic CKD/ESRD burden, with 25–40% of its population at risk [30]. Current estimates of CKD and ESRD in South Asia are approximately 800 and 100–200 per million people, respectively [26]. In China, the prevalence of CKD has been estimated to be 2–3% of the population or 10–15 million individuals [31].

### Table 1. Population incidence of CKD stages 1–5 in select countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Stage 1 (%)</th>
<th>Stage 2 (%)</th>
<th>Stage 3 (%)</th>
<th>Stage 4 (%)</th>
<th>Stage 5 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beijing study, China [14]</td>
<td>2.9</td>
<td>2.2</td>
<td>1.3</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>North Vietnam study, Vietnam [32]</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>3.6</td>
<td>–</td>
</tr>
</tbody>
</table>

---

6. See Appendix: KDOQI stages of CKD.
The increase in CKD and its progression to end-stage renal failure worldwide are mainly a result of the rising global diabetes and HT pandemics [21, 22, 32]. The Demand Project, led by Parving et al. [33], tested 31,470 diabetics across 34 countries, and showed that 49% of the subjects had microalbuminuria, a key CKD/ESRD marker. The 2000 AusDiab study showed that 25.4% of Australian individuals with HT and diabetes had microalbuminuria [18]. A study in southern China showed CKD in 27.3% of patients with DM and HT, and 26.4% of patients with metabolic syndrome or CVD [19]. A 2009 study conducted in the Congo showed that CKD was present in 44% of hypertensive patients and in 39% of diabetics [12]. The same study also showed a 16% CKD prevalence among obese patients and a 12% prevalence among HIV+ patients.

The progression of CKD to ESRD and its treatment depend heavily on the level of affluence of the country. Because of earlier stage mortality, LMICs have relatively low incidence rates of ESRD (150 per million people), as opposed to countries in North America and Europe [26]. Ninety percent of the 1.8 million people alive due to RRT reside in high-income countries [34]. Studies show that the incidence of ESRD has doubled in Europe and the USA over the past decade [19]. However, due to the rapid increase of several contributing risk factors, the number of ESRD patients in developing countries is expected to double to 2.1 million between 2001 and 2010 [35].

A survey across 10 Asian countries showed that the most common cause of ESRD in 9 out of 10 countries was diabetic nephropathy [13]. Diabetic nephropathy develops in 1 out of 3 diabetics worldwide, and is considered the leading cause of ESRD [13]. The remaining 66% of patients, mostly in developing countries, die from CVD prior to reaching ESRD, which contributes heavily to the burden of CVD (>30% of the global CD burden) [13]. However, estimated burdens of CKD in developing countries, most of which lack national renal disease registries, are often highly conservative representations of the overall national health burdens [36]. LMICs are not equipped to handle widespread screening for CKD, and surveillance studies are often limited to high-risk populations [16]. Furthermore, limited access to healthcare, lack of awareness, and limited capacity of health workers for CKD detection and prevention suggest that those in the lowest socioeconomic brackets are often unaware of any risk factors for CKD such as HT and DM. In Nepal, 47% of 1,243 subjects were newly diagnosed with HT [16]. In China, 75% of participants in a 2000 WHO study were newly diagnosed with diabetes [10]. In Pakistan, an estimated 70% of patients with high blood pressure and 50% of those with diabetes are unaware of their condition [37].

Fig. 2. Burden of mortality from kidney disease illustrated by relative country size (source: www.worldmapper.com). Territories are sized in proportion to the absolute number of people who died from kidney disease in 1 year. Copyright: SASI Group (University of Sheffield) and Mark Newman (University of Michigan).
The Economic Burden of CKD on Developing Countries

Economic growth studies suggest that the highest macroeconomic burden of CKD and other CDs falls on LMICs where high prevalence and the costs of treating disease create a greater proportional burden on the gross domestic product (GDP) (table 2). In 2005, CDs reduced GDP by an estimated 1% in Russia, and this number is expected to be over 5% by 2015 [2]. More recently, Abe-gunde and Stanciole [38] estimated the effects of 4 CDs on the economies of 23 high-burden developing countries using an economic growth model. These 23 countries account for approximately 80% of the total burden of CD mortality in developing countries. The study concluded that USD 84 billion of economic production will be lost due to heart disease, stroke, and diabetes in these countries between 2006 and 2015 [38].

Poverty and socioeconomic status are highly correlated with the common risk factors of CDs, including HT, DM, obesity, smoking, and dyslipidemia, making LMICs particularly vulnerable to the CD burden [3, 13]. Prevalence of HT in Brazil is consistently higher (by 30–130%) among the less educated, those in the lowest income bracket, and Afro-Brazilians [3]. Regions of low socioeconomic status are also less likely to have early detection and proper disease management [13]. In Jamaica, 59% of people with CDs had illness-related financial difficulties, and a high proportion admitted to avoiding some medical treatment because of these financial barriers [39]. CD events can result in ‘catastrophic’ health costs, pushing people into poverty. For example, in China, out-of-pocket expenses for stroke management pushed 37% of patients and their families below the poverty line – 62% were without insurance [40].

Much of the economic burden of CDs can be attributed to direct medical expenditures associated with expensive and long-term treatment costs. In LMICs, public health care systems receive only 0.8–4% of the GDP, as opposed to 10–15% in developed countries [37]. Countries with high prevalence of DM are projected to spend up to 40% of their health budgets on diabetes and diabetes-associated management, while the average among developed nations ranges between 2.5 and 15% [10]. In 2007, the global estimate of health care expenditure for diabetes was between USD 232 and 421 billion, and was predicted to double by 2025 [10, 41]. However, only 10% of these costs were borne by developing countries due to healthcare access, affordability, and treatment availability [6].

A similar trend can be seen with ESRD management, where developed countries dedicate more than 1% of the total health budget to the approximately 0.1% of the population that has ESRD [13]. However, ESRD management in LMICs is too expensive, and healthcare resources and budgets are unable to meet the burden of treatment. In Southeast Asia, RRT costs are more than 10 times the annual per capita income of approximately USD 400, and health insurance coverage is low or nonexistent for RRT/CKD treatment [32, 37].

These high costs and lack of access to RRT are why less than 10% of patients in developing countries receive RRT [37]. The financial adjustments, reduced savings, decreased investment potential, and constrained educational attainment that families face due to the CD burden result in detrimental macroeconomic impacts. Overall, these effects are likely to translate into significantly decreased economic growth, and compounded over time would adversely affect disease management and control in already resource-poor settings [2].

Cost-Effective Interventions

In the developing world, CKD prevention programs are relatively nonexistent. Current interventions for CDs in LMICs have focused primarily on CVD, diabetes, chronic respiratory disorders, and cancer [42]. CKD, de-

| Table 2. Share of cause-specific deaths (age <60 years) by country income level [55] |
|---------------------------------------------|--------|--------|--------|--------|
| (1) Communicable, maternal, perinatal and nutritional conditions | Low income | Lower-middle income | Upper-middle income | High income |
| (2) Chronic or noncommunicable conditions | 44% | 33% | 34% | 19% |
| (3) Injuries | 87% | 82% | 83% | 61% |

Burden of CKD on Developing Nations

Nephron Clin Pract 2011;118:c269–c277
Despite its numerous common modifiable risk factors and co-occurrence with many CDs, has not received the same kind of attention. This has been further exacerbated by lack of awareness, limited RRT availability, late referral of patients, and decreased capacity for CKD detection and prevention among healthcare practitioners [12].

Studies from developed countries show that mortality risk for CDs can be reduced by 75% through health interventions and the incidence can be reduced by up to 58% through lifestyle interventions [43]. Cost-effective population-based health intervention is based mainly on three major risk factors: poor diet, lack of physical activity, and tobacco use. This includes tobacco restrictions, salt reduction, elimination of caloric sweeteners, and fat substitution. For example, an increase in the tobacco price of 33% would cost USD 2–85 per Disability Adjusted Life Year (DALYA) [44]. Similarly, replacing trans fats with polyunsaturated fats would cost USD 25–75 per DALYA, and salt reduction can be achieved for less than USD 200 per DALYA. These interventions could extend to caloric sweeteners such as high-fructose corn syrup, which contribute to the obesity and metabolic syndrome epidemics in LMICs [45]. Cost-effective lifestyle and behavioral changes can also be achieved on a population basis through legislation, government influence, manufacturering changes, mass education campaigns and advertising bans [16, 44].

Arguably the most cost-effective solution for CKD and ESRD treatment in LMICs is renal transplantation, but this is heavily limited by cadaver availability and resources [26]. Thus, an emphasis on prevention planning and early detection of CKD on a long-term basis is the only practical and cost-effective solution for developing countries that cannot afford the burden of expensive treatment associated with CDs. Individual level interventions can be done through the screening of (high-risk) people and providing multidrug regimens of aspirin, ACE inhibitors, statin, calcium channel or β-blockers for early treatment [44]. Primary and secondary prevention using these medicines is projected to cost USD 350–825 per DALYA in LMICs. Potentially, a combination of these drugs with a diuretic and folic acid in the form of a single tablet, a ‘polypill’, could be used – this approach is still being tested in clinical trials [44]. Several countries have adopted prevention planning in their public health initiatives. One such example can be found in Uruguay, which established a program of preventive education for clinicians and patients to reduce the incidence and decrease health expenditures for kidney failure [25].

Currently, screening for CKD is accepted practice only in patients with HT or diabetes [46, 47]. A survey conducted on 65,604 people in Norway indicated that a high-risk screening model targeted at this population would identify less than half of those with CKD [48]. This suggests that screening of the general population should be proposed and implemented. Furthermore, early detection of CDs such as CKD, which are relatively asymptomatic, has a reasonable potential to have a positive impact on the outcome of the disease [16]. Studies in developed countries on the cost-effectiveness of tertiary prevention of CKD by treatment of HT, albuminuria, and use of renin-angiotensin system inhibitors have shown that early intervention appears to be more cost-effective than late intervention [49, 50]. Preventive education and early screening and identification would alleviate the economic burden of more advanced CKD and RRT treatments [16]. These alternatives and preemptive actions would also serve as low-cost solutions in managing the global trends of CKD and ESRD prevalence.

### Funding Needs

International donors are an important source of health care financing in LMICs. However, donors have almost completely neglected CDs, especially CKD. Of USD 21.7 billion in donor assistance for health in 2007, CDs received less than 3% [56]. This is consistent with several earlier analyses showing that donor assistance for health is heavily skewed towards infectious diseases, especially HIV/AIDS [51]. However, recent trends are progressing in the right direction. Global donor funding for CVD and other CDs increased from USD 236 million in 2004 to over USD 750 million in 2008 in real terms [56].

The largest proportional increase in donor funding comes from the private sector (mainly nonprofit) which collectively contributed over USD 267 million in 2008, constituting an almost 2,000% increase in private sector funding since 2004 [56]. CD funding from multilateral organizations increased from USD 175 million to USD 305 million, almost doubling between 2004 and 2008. Funding contributions from research institutions, public health organizations, and disease membership associations made up less than 3% of CD funding in all years between 2004 and 2008 [Nugent and Feigl, unpubl. data].
This diversification of funding is a positive trend, particularly because of the expertise and in-kind resources that private funders can bring; however, international and national governmental organizations should be encouraged to become more active in order to ensure accountability in global health equity. Despite the inadequate amount of funds, improvements can be made in the management and allocation of current appropriations. This limited and disproportionate funding focus on high-burden CDs is no longer a sustainable option, and funding must not only be increased but also designed to inclusively target the lowest socioeconomic regions in the world.

Time for Action

A comprehensive, integrated approach to managing the CD burden, with effective intervention tailored specifically to LMICs is essential to 21st century global health policy. There is a dire need for a greater alignment of global disease funding with CD burden, transparency of projects, data availability, and better sharing of knowledge for more targeted, effective, and coordinated activities to combat the global problem of CDs. Health interventions and international efforts must take the emerging burden of CKD among other CDs into account, especially as the overall population health burden due to CKD and its co-occurring pathologies are increasingly too great for many countries.

Aside from the specific cost-effective strategies to decrease the CD burden already mentioned, there are many more general strategies that can be implemented. In addressing the issues around common risk factors of CDs such as CKD, DM, and CVD, the preventive and primary health care systems of developing countries must be strengthened and unified. There is also a desperate need for public awareness and advocacy towards lifestyle changes and disease management, increased training and availability of medical practitioners, and for expanded surveillance and screening systems for CDs. The Disease Control Priorities Project offers such a recommendation, supporting the establishment of international centers of excellence for CKD that can work in tandem with centers of CVD and diabetes [52]. The International Society of Nephrology and Kidney Disease Improving Global Outcomes has responded to the challenging CKD burden by forming collaborations with societies such as the International Diabetes Federation (IDF), WHO, and the World Bank to influence global and national health decision-making as regards the growing burden of CKD and CVD. Other similar initiatives must now be brought forth and implemented [10, 45]. The time to act is now.

Appendix. KDOQI stages of CKD

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>GFR ml/min/1.73 m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Kidney damage with normal or ↑ GFR</td>
<td>≥90</td>
</tr>
<tr>
<td>2</td>
<td>Kidney damage with mild ↓ GFR</td>
<td>60–89</td>
</tr>
<tr>
<td>3</td>
<td>Moderate ↓ GFR</td>
<td>30–59</td>
</tr>
<tr>
<td>4</td>
<td>Severe ↓ GFR</td>
<td>15–29</td>
</tr>
<tr>
<td>5</td>
<td>Kidney failure, ESRD</td>
<td>&lt;15 (or dialysis)</td>
</tr>
</tbody>
</table>

CKD is defined as (1) persistent GFR <60 ml/min/1.73 m² for ≥3 months with or without kidney damage or (2) kidney damage for ≥3 months based on structural and functional anomalies of the kidney with or without decreased GFR [11]. GFR = Glomerular filtration rate.

References

Editorial Comment
Meguid El Nahas, Sheffield

The review by Nugent from the Center for Global Development and her colleagues highlights issues related to the impact of chronic kidney disease (CKD) on health in emerging economies. Such countries are the subject of a triple hit that leads to the development of CKD and impacts on population health and survival, poverty, infectious (communicable) disease as well as westernization with the sharp rise in noncommunicable chronic disease. The latter, as highlighted in the review, includes obesity with its impact on the development of diabetes, hypertension and cardiovascular disease (CVD). People in developing countries also live longer and this is associated with increased life course exposure to risk factors that lead to CKD and CVD. Cost-effective detection and management approaches are also advocated. They have to be adjusted to meet the local needs and means. They also have to take into consideration access to care and related cost. The 21st century with advances in telecommunication may open new and exciting opportunities to access healthcare in emerging countries. After all, before too long most people in those countries will have a mobile phone, but few will have access to a doctor! Perhaps, Mobile Health can be one way forward…